Replimune (REPL) Operating Income (2017 - 2026)
Replimune (REPL) posted Operating Income of -$73.3 million for Q1 2026, down 2.05% sequentially from -$71.9 million in Q4 2025, and up 7.55% YoY from -$68.2 million in Q1 2025.
Replimune (REPL) Operating Income (2017 - 2026) Analysis & Trends
Replimune has reported Operating Income for 10 years, with the latest figure at -$73.3 million in Q1 2026.
- Quarterly Operating Income rose 7.55% year-over-year to -$73.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319.9 million (down 22.28% YoY) and the FY2026 annual result came in at -$319.9 million, down 22.28% from the prior year.
- Operating Income eased to -$73.3 million in Q1 2026 per REPL's latest filing, from -$71.9 million in the prior quarter.
- Over five years, Operating Income peaked at -$32.0 million in Q1 2022 and troughed at -$90.4 million in Q2 2025.
- A 5-year average of -$60.3 million and a median of -$58.8 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income plunged 65.67% in 2023, then rose 7.7% in 2024.
- Over 5 years, Operating Income stood at -$41.6 million in 2022, then sank by 35.82% to -$56.5 million in 2023, then dropped by 16.77% to -$66.0 million in 2024, then retreated by 8.86% to -$71.9 million in 2025, then fell by 2.05% to -$73.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$73.3 million, -$71.9 million, and -$84.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | -73.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.34 Mn |
| Dec 31, 2025 | -71.87 Mn |
| Sep 30, 2025 | -84.29 Mn |
| Jun 30, 2025 | -90.42 Mn |
| Mar 31, 2025 | -79.33 Mn |
| Dec 31, 2024 | -66.02 Mn |
| Sep 30, 2024 | -58.92 Mn |
| Jun 30, 2024 | -57.37 Mn |
| Mar 31, 2024 | -58.76 Mn |
| Dec 31, 2023 | -56.54 Mn |
| Sep 30, 2023 | -63.83 Mn |
| Jun 30, 2023 | -55.65 Mn |
| Mar 31, 2023 | -53.00 Mn |
| Dec 31, 2022 | -41.63 Mn |
| Sep 30, 2022 | -41.58 Mn |
| Jun 30, 2022 | -40.88 Mn |
| Mar 31, 2022 | -31.99 Mn |
| Dec 31, 2021 | -29.70 Mn |
| Sep 30, 2021 | -29.25 Mn |
| Jun 30, 2021 | -27.38 Mn |